公开(公告)号：US08657775B2

公开(公告)日：2014-02-25

申请号：US12585054

申请日：2009-09-01

申请人： Colin Hutchison ,  Paul Cockwell ,  Hermann Göhl ,  Bernd Krause ,  Markus Storr

发明人： Colin Hutchison ,  Paul Cockwell ,  Hermann Göhl ,  Bernd Krause ,  Markus Storr

IPC分类号： A61M1/14 ,  A61M1/18 ,  A61M1/34 ,  B01D61/24 ,  B01D61/28 ,  B01D69/08 ,  B01D63/02

CPC分类号： B01D61/243 ,  A61M1/16 ,  B01D67/0013 ,  B01D69/08 ,  B01D69/12 ,  B01D2325/022 ,  B01D2325/20

摘要： The present invention relates to high cut-off hemodialysis membranes for the treatment of chronic hemodialysis (CHD) patients, with the potential to improve long-term survival of these patients by reducing the risk of cardiovascular disease, through down-regulation of monocyte activation in the blood. Monocytes are the major circulating blood cells involved in the progression of cardiovascular disease. High cut-off hemodialysis in chronic dialysis patients results in a sustained decrease in expression of monocyte cell-surface proteins that direct the movement of these cells from the blood to the walls of blood vessels, where they promote the progression of arterial disease (atherosclerosis) that leads to cardiovascular disease (CVD); heart disease, strokes and peripheral vascular disease.

摘要翻译： 本发明涉及用于治疗慢性血液透析（CHD）患者的高截止血液透析膜，可通过降低心血管疾病的风险来改善这些患者的长期存活，通过下调单核细胞活化 血液。 单核细胞是涉及心血管疾病进展的主要循环血细胞。 慢性透析患者的高截止血液透析导致单核细胞表面蛋白质的表达持续下降，从而将这些细胞从血液移动到血管壁，在那里它们促进动脉疾病（动脉粥样硬化）的进展， 导致心血管疾病（CVD）; 心脏病，中风和外周血管疾病。

公开(公告)号：US20100084339A1

公开(公告)日：2010-04-08

申请号：US12585054

申请日：2009-09-01

申请人： Colin Hutchison ,  Paul Cockwell ,  Hermann Göhl ,  Bernd Krause ,  Markus Storr

发明人： Colin Hutchison ,  Paul Cockwell ,  Hermann Göhl ,  Bernd Krause ,  Markus Storr

IPC分类号： B01D61/32

CPC分类号： B01D61/243 ,  A61M1/16 ,  B01D67/0013 ,  B01D69/08 ,  B01D69/12 ,  B01D2325/022 ,  B01D2325/20

摘要： The present invention relates to high cut-off hemodialysis membranes for the treatment of chronic hemodialysis (CHD) patients, with the potential to improve long-term survival of these patients by reducing the risk of cardiovascular disease, through down-regulation of monocyte activation in the blood. Monocytes are the major circulating blood cells involved in the progression of cardiovascular disease. High cut-off hemodialysis in chronic dialysis patients results in a sustained decrease in expression of monocyte cell-surface proteins that direct the movement of these cells from the blood to the walls of blood vessels, where they promote the progression of arterial disease (atherosclerosis) that leads to cardiovascular disease (CVD); heart disease, strokes and peripheral vascular disease.

摘要翻译： 本发明涉及用于治疗慢性血液透析（CHD）患者的高截止血液透析膜，可通过降低心血管疾病的风险来改善这些患者的长期存活，通过下调单核细胞活化 血液。 单核细胞是涉及心血管疾病进展的主要循环血细胞。 慢性透析患者的高截止血液透析导致单核细胞表面蛋白质的表达持续下降，从而将这些细胞从血液移动到血管壁，在那里它们促进动脉疾病（动脉粥样硬化）的进展， 导致心血管疾病（CVD）; 心脏病，中风和外周血管疾病。